Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

232.36 +0.07 (+0.03%)
Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
89 90 Next >
News headline image
Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea
From Healis Therapeutics
Via GlobeNewswire
News headline image
3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade ↗
These stocks don't offer the highest yields, but their payouts are growing fast. 
Via The Motley Fool
News headline image
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today? ↗
FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more. 
Via Benzinga
News headline image
3 Dividend Stocks That Are No-Brainer Buys Right Now ↗
These stocks check off multiple boxes for investors. 
Via The Motley Fool
News headline image
Is AbbVie Stock a Buy Now? ↗
Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable. 
Via The Motley Fool
AbbVie Inc. (NYSE: ABBV) Records 52-Week High Friday Morning
Via Investor Brand Network
News headline image
AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗
A Relative Strength Rating upgrade for AbbVie shows improving technical performance. 
Via Investor's Business Daily
News headline image
AbbVie Options Trading: A Deep Dive into Market Sentiment ↗
 
Via Benzinga
News headline image
5 Forever Dividend Stocks to Build Your Portfolio ↗
These five stocks are high quality and reliable. 
Via The Motley Fool
News headline image
3 Magnificent Growth Stocks to Buy Right Now ↗
These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects. 
Via The Motley Fool
News headline image
3 Cash Cows to Boost Your Confidence During the February Chill ↗
The market can be a tricky place. Bet on these cash cow stocks to help restore confidence and extract steady returns. 
Via InvestorPlace
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
AbbVie Inc. (NYSE: ABBV) Records 52-Week High Wednesday Morning
Via Investor Brand Network
News headline image
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
From FN Media Group LLC
Via GlobeNewswire
News headline image
Beyond Nvidia: How To Navigate Investing In Your 40s — Insights From Reddit ↗
A Reddit user reached out to the community seeking advice beyond the hunt for the "next NVIDIA Corp." Here's a sample of the responses. 
Via Benzinga
News headline image
2 Magnificent Dividend Growth Stocks to Load Up On Right Now ↗
These two dividend-growth stocks are fantastic buys. 
Via The Motley Fool
News headline image
AbbVie Analysts Boost Their Forecasts Following Strong Earnings ↗
AbbVie Inc (NYSE: ABBV) reported better-than-expected fourth-quarter earnings on Friday. 
Via Benzinga
News headline image
The 7 Best Momentum Stocks You Can Purchase Today ↗
If you’re looking for hot opportunities in the market, here are just a few of the best momentum stocks to buy today. 
Via InvestorPlace
News headline image
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks? ↗
These incredible businesses have long histories of successes behind them, and more to come. 
Via The Motley Fool
News headline image
These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy ↗
The drugmaker is handling its biggest obstacle yet relatively well. 
Via The Motley Fool
News headline image
Jim Cramer Looks At Blackstone, Praises MercadoLibre: 'They're Incredibly Smart' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Freeport-McMoRan Inc. (NYSE: FCX) could go higher by a "couple of points, once the Chinese start manipulating their market higher, but that’s all... 
Via Benzinga
News headline image
3 Stocks Just Hit New 52-Week Highs. Should You Still Be Buying? ↗
Letting your winners run is a proven way to generate extraordinary portfolio returns without cutting them off by taking profits. 
Via InvestorPlace
News headline image
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List ↗
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
News headline image
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024 ↗
Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge. 
Via InvestorPlace
News headline image
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst ↗
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
News headline image
7 Dividend Stocks Worth Holding for the Long Haul ↗
These dividend stocks are worth holding for the long term both for upside and income production that can add up quickly. 
Via InvestorPlace
News headline image
Why AbbVie Stock Flew Higher on Monday ↗
Investors and pundits alike continued to be impressed by the company's latest earnings report. 
Via The Motley Fool
News headline image
Drug Maker AbbVie Stock Sees RS Rating Jump To 81 ↗
AbbVie stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 78 to 81. 
Via Investor's Business Daily
News headline image
Better Dividend Stock: Pfizer vs. AbbVie ↗
Both offer above-average yields but which can deliver the most dividend income over the long run? 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
89 90 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.